Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

immune globulin subcutaneous (human) 10%, with recombinant human hyaluronidase (Hyqvia)

Notes:

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary immune globulin subcutaneous (human) 10%, with recombinant human hyaluronidase (Hyqvia) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Allergist or Neurologist
- Patient has documented contraindication, intolerance*, or treatment failure to immune globulin subcutaneous (human) 20% (Hizentra)

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary immune globulin subcutaneous (human) 10%, with recombinant human hyaluronidase (Hyqvia) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Allergist or Neurologist
- Patient has documented contraindication, intolerance*, or treatment failure to immune globulin subcutaneous (human) 20% (Hizentra)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary immune globulin
subcutaneous (human) 10%, with recombinant human hyaluronidase (Hyqvia) will
be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Allergist or Neurologist
- Patient has documented contraindication, intolerance*, or treatment failure to immune globulin subcutaneous (human) 20% (Hizentra)

kp.org

Revised: 09/10/20 Effective: 10/15/20 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

